SCHEMBL13833768

SCHEMBL13833768

Cc1cccc2c(=O)n(CC(F)F)cnc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.44
POLB P06746 1/20 0.41
USP19 O94966 1/20 0.41
CNR1 P21554 1/20 0.41
PARP1 P09874 1/20 0.41
ALDH1A1 P00352 2/20 0.41
THRB P10828 1/20 0.41
PDE7A Q13946 3/20 0.40
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
PDE7B Q9NP56 1/20 0.40
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
HTR7 P34969 1/20 0.38
TLR7 Q9NYK1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12862591 0.87 TLR7 (0.50) TRPA1SMN1; SMN2POLBUSP19PARP1
SCHEMBL15518945 0.83 CNR1 (0.41) TRPA1SMN1; SMN2CNR1ALDH1A1RAB9A
SCHEMBL13833767 0.82 TRPA1 (0.49) TRPA1SMN1; SMN2POLBCNR1PARP1
SCHEMBL12877789 0.82 SMN1; SMN2 (0.54) TRPA1SMN1; SMN2POLBUSP19PARP1
SCHEMBL30552837 0.81 TRPA1 (0.53) TRPA1SMN1; SMN2POLBUSP19PARP1
SCHEMBL30552846 0.81 TRPA1 (0.53) TRPA1SMN1; SMN2POLBUSP19PARP1
SCHEMBL30552929 0.81 TRPA1 (0.53) TRPA1SMN1; SMN2POLBUSP19PARP1
SCHEMBL13833763 0.80 TRPA1 (0.47) TRPA1SMN1; SMN2POLBCNR1PARP1
SCHEMBL15801421 0.78 TRPA1 (0.51) TRPA1SMN1; SMN2POLBUSP19PARP1
SCHEMBL30552896 0.78 TRPA1 (0.48) TRPA1SMN1; SMN2POLBPARP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2708540-B1 PYRIMIDO-DIAZEPINONE COMPOUND KYOWA HAKKO KIRIN CO LTD (JP) 2018-07-25 EP disclosed
US-9453021-B2 Pyrimidodiazepinone compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2016-09-27 US disclosed
US-9453021-B2 Pyrimidodiazepinone compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2016-09-27 US disclosed
US-20140171422-A1 PYRIMIDODIAZEPINONE COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-06-19 US disclosed
US-20140171422-A1 PYRIMIDODIAZEPINONE COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-06-19 US disclosed
WO-2012153796-A1 PYRIMIDO-DIAZEPINONE COMPOUND 協和発酵キリン株式会社 (JP) 2012-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171422-A1 PYRIMIDODIAZEPINONE COMPOUND REN, AGTR1, KCNJ1 TRPA1 2194/4885SMN1; SMN2 3656/4885POLB 2343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.